17th May 2016 06:24
LONDON (Alliance News) - AstraZeneca PLC Tuesday said it saw positive results from two phase III trials of benralizumab in severe asthma.
The company said that the drug was well tolerated and achieved its primary endpoint in the two trials, showing "significant reductions in the annual asthma exacerbation rate" compare to placebo.
"Benralizumab is AstraZeneca's first respiratory biologic and its development underscores our commitment to transform the treatment of asthma and chronic respiratory disease with our next generation of respiratory medicines," said Executive Vice President of Global Medicines Development and Chief Medical Officer Sean Bohen in a statement.
Regulatory submissions for benralizumab are anticipated in the second half of the year in the US and EU.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
Astrazeneca